Of note, chymase can directly promote IL-1β production (Mizutani et al., 1991), and other mast cell mediators might also contribute to IL-1β-driven disease in CRMO patients (Hofmann et al., 2015, 2016a). This evidence concerns the gene CMA1 and chronic recurrent multifocal osteomyelitis.